Krystal Biotech (KRYS) Bank of America Global Healthcare Conference 2026 summary

Financial performance and business model

• Achieved 11-12 consecutive quarters of positive EPS and gross margins in the 90-95% range, reflecting a sustainable business model uncommon in biotech.

• Ex-U.S. launches have exceeded expectations, with strong value propositions in France, Germany, and Japan; launches in Italy and Spain are ahead of schedule for the second half of the year.

• U.S. market penetration is at about 60% of identified patients, with ongoing growth expected as the company targets the full 1,200 identified patients and potentially up to 3,000 based on prevalence.

• Cost structure remains stable, with small teams per country and operating expenses for 2026 projected to be similar to last year, even as new assets enter the clinic.

• The $900K reimbursement cap in the U.S. is largely being phased out as payer confidence grows.

Global launch and revenue recognition

• Japan's commercial launch is progressing well, with positive pricing and a prescription renewal requirement for the first year.

• Germany and France are seeing strong patient uptake; pricing accruals are ongoing until final prices are set, expected in the second half of the year for Germany and continuing until 2027 for France.

• Italy and Spain launches will use a pricing-first model with no accruals, and patient prevalence is estimated at 275-350 per country.

• Physician awareness in Europe is high, aided by shared U.S. experiences and strong demand, particularly in Spain.

• Revenue reporting is shifting to split out Europe and Japan, moving away from using rough patient number proxies.

Pipeline and clinical development

• KB803 for ocular DEB is fully enrolled, using a crossover, double-blind, placebo-controlled design, with endpoints based on patient-reported outcomes and a scale developed from a natural history study.

• Most patients in the ocular DEB study overlap with those on the main product, with about half the rDEB and a portion of dDEB populations eligible.

• Commercial launch of KB803 could leverage the existing sales force, as prescribing physicians are largely the same.

• KB801 for neurotrophic keratitis is a patient-administered therapy, with a study expanded to 60 patients and endpoints based on independent photographic assessment of healing.

• The cystic fibrosis program has demonstrated molecular correction and is moving into a repeat-dose safety study, with pivotal trial design discussions ongoing and expected to be finalized by year-end.